Lower Dose of Mpox Vaccine Is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen | The GW Vaccine Research Unit

April 29, 2024

Authored by

National Institute of Allergy and Infectious Diseases

NIAID Image

Findings were published on a recent study that GW VRU participated in as a site.

Click here to read the NIAID news release.

Latest News

A needle withdraws the vaccine in an RSV vial.

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

October 24, 2024

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

mpox virus particles from NIAID Integrated Research Facility (credit: NIAID)

Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents

October 16, 2024

Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

September 26, 2024

Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.